Recent advances in the design of small molecular drugs with acrylamides covalent warheads
- PMID: 39236467
- DOI: 10.1016/j.bmc.2024.117902
Recent advances in the design of small molecular drugs with acrylamides covalent warheads
Abstract
In the development of covalent inhibitors, acrylamides warhead is one of the most popular classes of covalent warheads. In recent years, researchers have made different structural modifications to acrylamides warheads, resulting in the creation of fluorinated acrylamide warheads and cyano acrylamide warheads. These new warheads exhibit superior selectivity, intracellular accumulation, and pharmacokinetic properties. Additionally, although ketoamide warheads have been applied in the design of covalent inhibitors for viral proteins, it has not received sufficient attention. Combined with the studies in kinase inhibitors and antiviral drugs, this review presents the structural features and the progression of acrylamides warheads, offering a perspective on future research and development in this field.
Keywords: Acrylamide; Covalent warhead; Inhibitors; Small molecular drug.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Screening of Covalent Kinase Inhibitors Yields Hits for Cysteine Protease USP7 / HAUSP.Drug Des Devel Ther. 2025 Mar 25;19:2253-2284. doi: 10.2147/DDDT.S513591. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40165995 Free PMC article.
-
Residue-Selective Inhibitors Discovery via Covalent DNA-Encoded Chemical Libraries with Diverse Warheads.J Am Chem Soc. 2025 May 7;147(18):15469-15481. doi: 10.1021/jacs.5c01712. Epub 2025 Apr 28. J Am Chem Soc. 2025. PMID: 40292872
-
Application of Dually Activated Michael Acceptor to the Rational Design of Reversible Covalent Inhibitor for Enterovirus 71 3C Protease.J Med Chem. 2019 Jul 11;62(13):6146-6162. doi: 10.1021/acs.jmedchem.9b00387. Epub 2019 Jun 27. J Med Chem. 2019. PMID: 31184893
-
Innovative design and potential applications of covalent strategy in drug discovery.Eur J Med Chem. 2025 Feb 15;284:117202. doi: 10.1016/j.ejmech.2024.117202. Epub 2024 Dec 26. Eur J Med Chem. 2025. PMID: 39756145 Review.
-
Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.J Med Chem. 2022 Jan 13;65(1):58-83. doi: 10.1021/acs.jmedchem.1c01719. Epub 2021 Dec 28. J Med Chem. 2022. PMID: 34962782 Review.
Cited by
-
Identification of a novel allosteric binding site on the catalytic domain of NF-κB inducing kinase (NIK).RSC Med Chem. 2025 Feb 7. doi: 10.1039/d4md00963k. Online ahead of print. RSC Med Chem. 2025. PMID: 39990163 Free PMC article.
-
Morita-Baylis-Hillman Adduct Chemistry as a Tool for the Design of Lysine-Targeted Covalent Ligands.ACS Med Chem Lett. 2025 Feb 28;16(3):397-405. doi: 10.1021/acsmedchemlett.4c00479. eCollection 2025 Mar 13. ACS Med Chem Lett. 2025. PMID: 40104796
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources